The Omnipresence of DYRK1A in Human Diseases
Open accessThe DOI matches its Crossref record; 144 of the 144 references it cites were found in a registry or an index.
Abstract
The increasing population will challenge healthcare, particularly because the worldwide population has never been older. Therapeutic solutions to age-related disease will be increasingly critical. Kinases are key regulators of human health and represent promising therapeutic targets for novel drug candidates. The dual-specificity tyrosine-regulated kinase (DYRKs) family is of particular interest and, among them, DYRK1A has been implicated ubiquitously in varied human diseases. Herein, we focus on the characteristics of DYRK1A, its regulation and functional role in different human diseases, which leads us to an overview of future research on this protein of promising therapeutic potential.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 DYRK family of proteins origins and specificities in humans (based on [10,14,15,16,17,18,19,20]). The percentage of conservation at the protein level between orthologues is indicated above the arrows and between two paralogues is indicated in parentheses within the boxes.](https://figures.cochat.ai/paper-figures/2031cafd490f4ed6b329324cb44c3e7b/the-omnipresence-of-dyrk1a-in-human-diseases-figure-1.jpg)
![Figure 2 Schematic representation of the protein sequences of the 5 human DYRKs (from uniport.org and based on [10,24]). The different protein motifs identified are indicated: NLS, nuclear localization signal; DH, DYRK-homology box; NAPA, N-terminal autophosphorylation accessory region; kinase, kinase domain; PEST, motif rich in proline, glutamic acid, serine, and threonine residues; His, polyhistidine domain; S/T, serine and threonine-enriched domain; and Y, tyrosine residue autophosphorylated by DYRKs within the activation loop. Turquoise lines indicate protein regions affected by alternative splicing events.](https://figures.cochat.ai/paper-figures/489442554f2f4f6e8bc3369a33e3aeaa/the-omnipresence-of-dyrk1a-in-human-diseases-figure-2.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Given that overexpression of dual-specificity tyrosine phosphorylation-regulated kinase 1 A (DYRK1A) may influence the initial progression of AD through mechanisms including the hyperphosphorylation of pathologically relevant substrates such as tau, APP, PS1, regulation of axonal transport of APP, and participation in the selective splicing of tau pre-mRNA,500–502”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [502]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
Benjamin, E. J., Muntner, P., Alonso, A., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Das, S. R., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000659 · Cited by 9,036
The protein kinase complement of the human genome
Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002) · Science · doi:10.1126/science.1075762 · Cited by 8,145 · cited 3×
“kinases (GSKs) and CDK-like kinases (CLKs), collectively called the CMGC family [5].”
BackgroundMicroRNA therapeutics: towards a new era for the management of cancer and other diseases
Rupaimoole, R., & Slack, F. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.246 · Cited by 4,741
Jones, P. A., & Baylin, S. B. (2007) · Cell · doi:10.1016/j.cell.2007.01.029 · Cited by 4,515
Diagnosis and Treatment of Parkinson Disease: A Review
Armstrong, M. J., & Okun, M. S. (2020) · JAMA · doi:10.1001/jama.2019.22360 · Cited by 2,924
Knopman, D. S., Amieva, H., Petersen, R. C., Chételat, G., Holtzman, D. M., Hyman, B. T., Nixon, R. A., & Jones, D. T. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00269-y · Cited by 2,606
Epidemiology of Diabetes and Diabetes-Related Complications
Deshpande, A. D., Harris-Hayes, M., & Schootman, M. (2008) · Physical Therapy · doi:10.2522/ptj.20080020 · Cited by 1,773
Trends in kinase drug discovery: targets, indications and inhibitor design
Attwood, M. M., Fabbro, D., Sokolov, A. V., Knapp, S., & Schiöth, H. B. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00252-y · Cited by 779 · cited 1×
“Mutations in kinases and the deregulated signaling that results are frequently the cause of many human diseases [6,8,9].”
BackgroundNFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21
Arron, J. R., Winslow, M. M., Polleri, A., Chang, C.-P., Wu, H., Gao, X., Neilson, J. R., Chen, L., Heit, J. J., Kim, S. K., et al. (2006) · Nature · doi:10.1038/nature04678 · Cited by 698
A brief history of human disease genetics
Claussnitzer, M., Cho, J. H., Collins, R., Cox, N. J., Dermitzakis, E. T., Hurles, M. E., Kathiresan, S., Kenny, E. E., Lindgren, C. M., MacArthur, D. G., et al. (2020) · Nature · doi:10.1038/s41586-019-1879-7 · Cited by 697 · cited 1×
“Over the past 25 years, technological advances in genomics and analytical approaches have permitted the dissection of the human genome in unprecedented depth, greatly expanding our understanding of many diseases, and facilitating the identification of currently understudied, but potentially druggable, proteins [3,4].”
Background
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
“…relevant substrates such as tau, APP, PS1, regulation of axonal transport of APP, and participation in the selective splicing of tau pre-mRNA, 500 – 502 the compound dp-FINDY ( 37 ) effectively targets the spatial dynamic changes in the ATP-binding site between the DYRK1A folding intermediate and…”
BackgroundComparative Efficacy and Selectivity of Pharmacological Inhibitors of DYRK and CLK Protein Kinases
Lindberg, M. F., Deau, E., Arfwedson, J., George, N. S., George, P. G., Alfonso, P., Corrionero, A., & Meijer, L. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c02068 · Cited by 54
Lindberg, M. F., Deau, E., Miege, F., Greverie, M., Roche, D., George, N. S., George, P. G., Merlet, L., Gavard, J., Brugman, S. J. T., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01888 · Cited by 52
Deau, E., Lindberg, M. F., Miege, F., Roche, D., George, N. S., George, P. G., Krämer, A., Knapp, S., & Meijer, L. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00884 · Cited by 41
Meijer, L., Chrétien, E., & Ravel, D. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240078 · Cited by 33
Down syndrome and DYRK1A overexpression: relationships and future therapeutic directions
Murphy, A. J., Wilton, S. D., Aung-Htut, M. T., & McIntosh, C. S. (2024) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2024.1391564 · Cited by 30
“Should a DYRK1A inhibitor become available, this would not be limited to a treatment for DS as it would have benefits for cancers, Alzheimer’s disease, viral infections, heart disease, Huntington’s disease, among others (Deboever et al., 2022).”
BackgroundChen, H., Gao, X., Li, X., Yu, C., Liu, W., Qiu, J., Liu, W., Geng, H., Zheng, F., Gong, H., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00483 · Cited by 29
Insights from the protein interaction Universe of the multifunctional “Goldilocks” kinase DYRK1A
Ananthapadmanabhan, V., Shows, K. H., DICKINSON, A. J. G., & Litovchick, L. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1277537 · Cited by 23
Plasma p‐tau212 as a biomarker of sporadic and Down syndrome Alzheimer's disease
Kac, P. R., Alcolea, D. A., Montoliu‐Gaya, L., Fernández, S., Lantero‐Rodriguez, J., Maure‐Blesa, L., González‐Ortiz, F., Benejam, B., Turton, M., Barroeta, I., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70172 · Cited by 23
Wu, Y., Zou, Y., Song, C., Cao, K., Cai, K., Chen, S., Zhang, Z., Geng, D., Zhang, N., Feng, H., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117093 · Cited by 22
Wilms, G., Schofield, K., Maddern, S., Foley, C., Shaw, Y., Smith, B. E., Basantes, L. E., Schwandt, K., Babendreyer, A., Chavez, T., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01130 · Cited by 19
Self-citationAcridine: A Scaffold for the Development of Drugs for Alzheimer's Disease
Sharma, A., & Piplani, P. (2023) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026623666230203141543 · Cited by 19
Bioactivities and Structure–Activity Relationships of Harmine and Its Derivatives: A Review
Liu, Q., Yang, C., Qi, J., Shen, Q., Ye, M., Li, H.-Y., & Zhang, L. (2025) · Chemistry & Biodiversity · doi:10.1002/cbdv.202402953 · Cited by 15
“GSK-3 β and dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) are crucial in neurodegenerative diseases, with their dysregulation associated with many CNS diseases (Figure 3) [83, 84].”
Kršek, A., Schleicher, L. M. S., Jagodic, A., & Batičić, L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26189178 · Cited by 16
“DYRK1A dysregulation is implicated in neurodegenerative diseases, notably Down syndrome and AD [144].”
Bertrand, R., Tolu, S., Picot, D., Tourrel‐Cuzin, C., Ouahab, A., Dairou, J., Deau, E., Lindberg, M. F., Meijer, L., Movassat, J., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102242 · Cited by 13
“DYRK1A is ubiquitously expressed and has attracted increasing interest as a potential therapeutic target in various diseases such as Alzheimer’s disease, Down syndrome and leukemias [8,10,12,13].”
CK2 Inhibitors Targeting Inside and Outside the Catalytic Box
Day-Riley, S., West, R. M., Brear, P., Hyvönen, M., & Spring, D. R. (2024) · Kinases and Phosphatases · doi:10.3390/kinasesphosphatases2020007 · Cited by 13
“More-over, 108600 displayed IC 50 values for CK2 α , CK2 α ’, TNIK, DYRK1A, and DYRK1B of 50, 5, 5, 16, and 7 nM. Surprisingly, 108600’s inhibitory activity against the CK2 α isoform is 10-fold higher than the CK2 α ’ isoform, indicating potential for isoform-selective derivatives to be developed.”
BackgroundFu, Z., Xiang, Y., Fu, Y., Su, Z., Tan, Y., Yang, M., Yan, Y., Daemi, H. B., Shi, Y., Xie, S., et al. (2023) · Journal of Virology · doi:10.1128/jvi.01239-23 · Cited by 12
Chen, J. J., Tu, H., Lin, T. E., Peng, Z., Wu, Y., Yen, S., Sung, T.-Y., Hsieh, J., Lee, H., Pan, S., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117688 · Cited by 11
Structural perspective on the design of selective DYRK1B inhibitors
Grygier, P., Pustelny, K., Menezes, F., Jemioła‐Rzemińska, M., Suder, P., Dubin, G., & Czarna, A. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.148124 · Cited by 11
Psychoplastogenic DYRK1A Inhibitors with Therapeutic Effects Relevant to Alzheimer’s Disease
Warren, H. T., Saeger, H. N., Tombari, R. J., Chytil, M., Rasmussen, K., & Olson, D. E. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01696 · Cited by 10
Faouzi, A., Arnaud, A., Hallé, F., Roussel, J., Aymard, M., Denavit, V., Do, C. V., Mularoni, A., Salah, M., ElHady, A. K., et al. (2024) · RSC Medicinal Chemistry · doi:10.1039/d4md00537f · Cited by 10
Pustelny, K., Grygier, P., Barzowska, A., Pucelik, B., Matsuda, A., Mrowiec, K., Sługocka, E., Popowicz, G. M., Dubin, G., & Czarna, A. (2023) · Scientific Reports · doi:10.1038/s41598-023-44810-3 · Cited by 9
“The DYRK1A kinase has been implicated in various human diseases, mainly in diabetes mellitus and neurological disorders 77 .”
BackgroundSkeletal health in DYRK1A syndrome
Otte, E. D., & Roper, R. J. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1462893 · Cited by 9
“DYRK1A/MNB is involved in the phosphorylation of microtubule dynamics, which help to regulate dendritic patterning and neuronal function (Ori-McKenney et al., 2016; Deboever et al., 2022).”
BackgroundInfluentialPucelik, B., Barzowska, A., & Czarna, A. (2023) · PLoS ONE · doi:10.1371/journal.pone.0285208 · Cited by 9
“Growing evidence indicates that inhibition of DYRK1A is critical for β cell restoration and confirm that the DYRK1A signaling pathway is deregulated in diabetes [8, 12, 57, 77].”
BackgroundRozen, E. J., Dowell, R. D., & Allen, M. A. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1587089 · Cited by 8
Kohal, R., Bhavana, Kumari, P., Sharma, A. K., Gupta, G. D., & Verma, S. K. (2024) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2024.129674 · Cited by 8
Falgàs, N., Maure‐Blesa, L., Ances, B. M., Aguilar, L. F., Hartley, S. L., Hassenstab, J. J., Iulita, M. F., Janicki, M. P., Koenig, K. A., Lao, P. J., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70309 · Cited by 7
DYRK1A in the physiology and pathology of the neuron-astrocyte axis
Cisternas, P., Kim, J.-Y., Ashfeld, B. L., & Zartman, J. J. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1626062 · Cited by 7
“Importantly, astrocytic tau aggregation has been observed in several neurological conditions, such as AD (Dabir et al., 2004; Ferrer et al., 2014; Iwatsubo et al., 1994; Nakano et al., 1992; Nolan et al., 2019), in tauopathies like CBD, PiD, PSP, FTD and argyrophilic grain disease (AGD) (Botez et al., 1999; Briel et a…”
InfluentialHuang, C.-S., Hsieh, M., Yadav, V. K., Wu, Y., Liu, S., Yeh, C., & Huang, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417346 · Cited by 7
“Recent studies suggest that alterations in DYRK gene expression may contribute to tumorigenesis and/or disease progression, making DYRK kinases an intriguing area of research [12].”
Paclibar, C. G., Schafer, D. M., Biju, A. P., Karim, F., Sison, S. A., Liang, C., Ahmed, S. T., & Mukherjee, J. (2025) · Molecules · doi:10.3390/molecules30050990 · Cited by 6
Karati, D., Meur, S., Saha, A., Saha, T., & Sen, A. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-04806-8 · Cited by 6
“Tau is phosphorylated by DYRK1A on a number of sites, including Thr212 and Ser396, which primes tau for additional phosphorylation by GSK3β [113].”
The Role of Goldilocks Protein Kinase DYRK1A in Embryonic Development
Johnson, H. K., Litovchick, L., & DICKINSON, A. J. G. (2025) · Developmental Biology · doi:10.1016/j.ydbio.2025.06.009 · Cited by 6
Pastor, F., Charles, E. M., Vona, C. D., Chapelle, M., Rivoire, M. L., Passot, G., Chabot, B., de la Luna, S., Lucifora, J., Durantel, D., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0311655 · Cited by 5
“DYRK1A is an essential gene in mammals, whose alterations in expression have been associated with different human diseases including Down syndrome when present in trisomy or a neurodevelopmental syndrome when in haploinsufficiency [66].”
BackgroundWest, N. R., Lindberg, M. F., Dairou, J., MacGregor, S., Puthireddy, S., Meijer, L., & Bhattacharyya, A. (2026) · Disease Models & Mechanisms · doi:10.1242/dmm.052740 · Cited by 4
“It is ubiquitously expressed across development in several tissues, including the brain (Atas-Ozcan et al., 2021; Guimera et al., 1999; Deboever et al., 2022; Becker and Joost, 1998; Hämmerle et al., 2008).”
InfluentialWang, L., Liu, H., Chen, G., Wu, Q., Xu, S., Zhou, Q., Zhao, Y., Wang, Q., Yan, T., & Cheng, X. (2025) · Cancer Gene Therapy · doi:10.1038/s41417-025-00889-6 · Cited by 4
“Previous studies have demonstrated that DYRK1A is a dual-speci fi c tyrosine-phosphorylation-regulated kinase that plays an important role in various biological processes, especially in neurodevelopment, cell proliferation, and differentiation [43].”
Paolo, M. L. D., Salerno, S., Nordio, G., Piazzola, F., Sarno, S., Sarno, G., Natale, B., Poggetti, V., Borreca, A., Baglini, E., et al. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117580 · Cited by 4
Aoyama, M., Kimura, N., Yamakawa, M., Suzuki, S., Umezawa, K., & Kii, I. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.149220 · Cited by 4
Keddis, P. M., Tu, T.-K. M., Scherer, H., Kany, A. M., Hafez, D. E., Darwish, S. S., Abadi, A., Hirsch, A. K. H., Engel, M., Hamed, M. M., et al. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117348 · Cited by 4
Yuan, R., Sun, Q.-C., An, Y., Zhang, Q. H., Zhang, Q., & Li, Y. (2025) · Journal of Asian Natural Products Research · doi:10.1080/10286020.2024.2446301 · Cited by 3
Alam, P., Arshad, M. F., & Sharma, P. K. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-04935-0 · Cited by 3
“Therefore, a balance in DYRK1 A protein level is highly required [12].”
DYRK1A and Parkinson’s disease, facts and hypotheses
Meijer, L., Lindberg, M. F., Hogrel, G., & Khor, B. (2026) · Neurobiology of Disease · doi:10.1016/j.nbd.2026.107379 · Cited by 3
Borisevich, S. S., Aksinina, T. E., Ilyina, M. G., Shender, V. О., Anufrieva, K. S., Arapidi, G. P., Антипова, Н. В., Anizon, F., Esvan, Y. J., Giraud, F., et al. (2024) · Cancers · doi:10.3390/cancers16040834 · Cited by 3
“Overall, the differential donor-acceptor nature of the substituent is a critical prerequisite for the rational design of pyrido[3,4-g ]quinazoline-based splicing antagonists.”
BackgroundMethodInfluentialWhitaker, F., & Serrano, A. (2024) · Case Reports in Genetics · doi:10.1155/2024/2926555 · Cited by 2
“Activation of DYRKs depends on the autophosphorylation of a tyrosine residue in the activation loop [1].”
BackgroundAraldi, G. L., Hwang, Y., & Raghu, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252111827 · Cited by 2
Ganguly, B. B., & Kadam, N. N. (2025) · Gene Expression · doi:10.14218/ge.2025.00051 · Cited by 2
Detro‐Dassen, S., Schwandt, K., Helmich, P., Düsterhöft, S., & Becker, W. B. (2025) · Scientific Reports · doi:10.1038/s41598-025-33562-x · Cited by 2
FAM117B Promotes Colorectal Cancer Progression by Enhancing DYRK1A‐mediated Phosphorylation of PLK2
Yu, Z., Zhou, C., Chen, H., Xu, K., & Li, C. (2026) · Cell Biology International · doi:10.1002/cbin.70122 · Cited by 2
“Dual specificity tyrosine (Y)‐regulated kinase 1 A (DYRK1A), is the product of a dosage‐sensitive gene residing in the Down syndrome critical region on human chromosome 21 (Deboever et al. 2022).”
Deau, E., Simon, C., Hogrel, G., CAILLETTE, J., Dairou, J., Hérault, Y., Morlet, B., Miyata, Y., Meijer, L., & Lindberg, M. F. (2026) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.6c00066 · Cited by 2
Qiao, P., Zhu, Y., Zhang, J., Gan, Y., Wang, Y. Q., Li, Y., Li, Z., Xue, H., & Liu, L. (2026) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2026.112184 · Cited by 2
Dyr726, a brain-penetrant inhibitor of PI3Kα, Type III receptor tyrosine kinases, and WNT signalingPreprint
Tandon, V., Fistrovich, A., Nogales, J., Ferro, F., Rokey, S., Cabel, C. R., Miller, A. D., Yagel, M., Duncan, C., Atmasidha, A. M., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.26.645490 · Cited by 2
Self-citationYamada, N., Suzuki, S., Fukahori, N., Yamaoka, Y., Komiyama, Y., Kimura, N., Umezawa, K., & Kii, I. (2025) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2025.130527 · Cited by 1
Epigenetic treatment of synaptic and behavioral deficits in Dyrk1a-mutant mice
Lin, C.-H., Yu, M., Patel, P. J., Li, P., & Yan, Z. (2026) · Neuropsychopharmacology · doi:10.1038/s41386-026-02353-x · Cited by 1
Inhibition of Dyrk1a attenuates type 1 diabetic cardiomyopathy via anti‑ferroptosis
Chen, J., Zhang, W., Hong, T., Wang, J., Chen, C., Zhang, Y., Hu, M., You, N., & Huang, J. (2026) · Molecular Medicine Reports · doi:10.3892/mmr.2026.13996 · Cited by 1
“Therefore, the present study subsequently examined Dyrk1a, a kinase implicated in diverse pathologies comprising dementia, diabetes and cardiovascular disorders (40).”
The level of dementia biomarkers in type 2 diabetes mellitus
Özpak, L., Şahin, M., ÇELİK, İ. S., KELLECİ, B. M., & Çelik, M. (2023) · Çukurova medical journal (Online)/Çukurova medical journal · doi:10.17826/cumj.1311596
“Beta cell proliferation is essential for providing endogenous insulin in diabetes mellitus, and studies have shown that inhibition of DYRK1A induces human beta cell proliferation 5 .”
DYRK1A Proteins: Key Regulators in Neurodevelopment and Cellular Processes
Uğur, E., & Arslan, İ. (2025) · Lecture notes in networks and systems · doi:10.1007/978-3-031-95200-5_30
Hou, Z., Zhang, T., Zhang, C., Ding, Z., Wang, P., Pan, X., & Li, X. (2025) · Genomics · doi:10.1016/j.ygeno.2025.111081
Soliman, M., Mostafa, N. S., Mahmoud, S. T., El‐Gamil, D. S., Abdel‐Halim, M., & Fouad, M. M. (2025) · Journal of Chromatography B · doi:10.1016/j.jchromb.2025.124888
Cholesterol, lipid metabolism, and lipid rafts in Alzheimer's disease
Taghibiglou, C., Pordeli, M., Setork, E., & Cayabyab, F. S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-30008-0.00010-7
Vyas, J., Jamenis, A. S., Kaku, K., Shah, Y. V., Miner, K. M., Bhatia, T. N., Kim, R. E., Bai, R., Hamel, E., Leak, R. K., et al. (2026) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2026.130536
Liu, L., Qiao, P., Gan, Y., Fu, X., Huang, X., Sun, S., Gou, Y., Xia, W., Ma, F., & Liu, L. (2026) · MedComm – Future Medicine · doi:10.1002/mef2.70050
CMGC Kinases in Viral Infection and Human Disease
Amusan, O. T., & Guo, H. (2026) · Pathogens · doi:10.3390/pathogens15040366
Chimie du Sel d'Appel et des Acides Anthraniliques pour la synthèse de nouveaux hétérocycles.
Broudic, N. (2024) · theses.fr (ABES) · doi:10.70675/eb6cccdfza05dz48c2za800za8c5dff96e83
Probing Allosteric Kinase Modulators as Next Game-Changers in Fighting Neurodegeneration
Roggiolani, E., Rosini, M., Minarini, A., & Basagni, F. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03783
Orchestrating mitochondrial protein import: The emerging role of DYRK1A in health and disease
Shankar, S., & Meisinger, C. (2026) · Protein Science · doi:10.1002/pro.70631
Uría-Gómez, C. E., Zerón, H. M., Arteaga‐Vázquez, J., & Sandoval-Cabrera, A. (2026) · Oncology Letters · doi:10.3892/ol.2026.15678
“However, the role of DYRK1A remains to be elucidated, as there are several studies indicating that it has both oncogenic and tumor suppressor functions (27,28).”
HirschsprungÓ?s disease and Mowat-Wilson syndrome: should a pull-through be performed?
Martain-Pérez, I., Dávila-Pérez, R., Fernández-Portilla, E., Lizarraga-Rodriguez, I., Moreno‐Salgado, R., Nieto‐Zermeño, J., Costa-Roig, A., & Domínguez-Muñóz, A. (2026) · Boletín Médico Del Hospital Infantil de México (English Edition) · doi:10.24875/bmhime.m25000121
Abdallah, M., Keddis, P. M., Keddis, T. M., El‐Gamil, D. S., Abadi, A. H., Kii, I., Engel, M., & Abdel‐Halim, M. (2026) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2026.2694586
“Once activated, DYRK1A functions predominantly as a serine/threonine kinase, targeting a broad spectrum of nuclear and cytoplasmic substrates [9].”
Yu, M., Tang, S., Huang, L., Wang, Y., Xu, J., Zhu, H., & Yao, H. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00774
Integrative Insights Into DYRK1A From Molecular Function to Therapeutic Advancement
Paul, S., Dubey, S., & Tiwari, P. K. (2026) · Chemical Biology & Drug Design · doi:10.1111/cbdd.70366
Poonam, Rana, R., Thakur, M., Sharma, A., Pannu, S., Sharma, S., Naman, S., Rani, S., Devi, D., Kumar, V., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1908830
“This approach lessens unnecessary disruption to the protein ’ s normal functions while creating new opportunities for developing more targeted and accurate therapies (219 – 221).”
Transcriptional modulators on chromosome 21 and their relationship to Down syndrome
Sullivan, M., Kurland, J. V., Ozeroff, C., Logsdon, D., Dowell, R. D., Allen, M., & Rozen, E. J. (2026) · Genes & Diseases · doi:10.1016/j.gendis.2026.102574
The role of immune-related transcription factors as a therapeutic approach to Parkinson’s disease
Ekrani, S. T., Faraj, T. A., Wlia, A. B., & Esmaeili, S. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-13155-1
Metadata
- Authors
- Deboever, E., Fistrovich, A., Hulme, C., & Dunckley, T.
- Affiliations
- Arizona State University (US)
- University of Arizona (US)
- Corresponding author
- Deboever, Estelle
- Dunckley, Travis
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-08-19
- Volume
- 23
- Issue
- 16
- Pages
- 9355
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC9408930
- OpenAlex
- W4293678299
- Cited by
- 77
- References
- 143
- Citations by year
- 2026: 20 · 2025: 26 · 2024: 20 · 2023: 11
- FWCI
- 2.38
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Edson Family Foundation (38526, 1R01NS109422-01A1)
- NIA grant (38526, 1R01NS109422-01A1)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- DYRK1A, kinases, age-related diseases, therapeutic target, kinase regulation, human disease, drug candidates
- MeSH terms
- Dyrk Kinases, Disease, Humans, Protein-Tyrosine Kinases, Protein Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.